Related Experiment Video
Updated: Jun 6, 2026
09:05
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
Published on: May 4, 2015
Pharmacoinvasive therapy for acute myocardial infarction
1Department of Cardiology, Rashid Hospital, Dubai, United Arab Emirates. skacardio@yahoo.com
Summary
This case report details successful management of acute ST-elevation myocardial infarction (STEMI) using intracoronary thrombolytic therapy, thrombectomy, and percutaneous coronary intervention (PCI). This combination approach offers a potential strategy for complex thrombus cases in interventional cardiology.
Area of Science:
- Interventional Cardiology
- Cardiovascular Medicine
- Thrombosis Management
Background:
- Thrombus burden presents a significant challenge in interventional cardiology.
- Current strategies for thrombus management during percutaneous coronary intervention (PCI) remain debated.
- Intracoronary (IC) thrombolytic therapy is not a standard approach, unlike intravenous thrombolysis for acute ST-elevation myocardial infarction (STEMI).
Observation:
- A patient presented with acute ST-elevation myocardial infarction (STEMI).
- The patient's condition involved significant thrombus burden.
- Standard PCI procedures were considered alongside adjunctive therapies.
Findings:
- Successful management was achieved using a combined therapeutic approach.
- The strategy involved intracoronary (IC) thrombolytic therapy.
- This was coupled with the use of a thrombectomy device and percutaneous coronary intervention (PCI).
Implications:
- This case suggests a potential effective strategy for managing STEMI with substantial thrombus.
- The combination of IC thrombolysis, thrombectomy, and PCI may be a viable option for complex cases.
- Further research could explore the broader applicability and outcomes of this multimodal approach in interventional cardiology.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...